Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
Biol (Basel)
This beauty supplement is crafted to support a radiant complexion and youthful skin health as part of your balanced daily routine
The group noted alterations in CD31 and ZO-1 localization at endothelial junctions upon exposure to lipedema-SVF conditioned media
Bondeson DP, Mares A, Smith IED, Ko E, Campos S, Miah AH, et al
In cosmetic formulation, it functions as a potent skin brightening active by inhibiting tyrosinase, the enzyme that drives melanin synthesis, and redirecting melanogenesis from the darker eumelanin pathway to the lighter phaeomelanin pathway